Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-11-22
2008-08-26
O'Hara, Eileen B. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S198000, C530S388260, C530S387100
Reexamination Certificate
active
07416853
ABSTRACT:
The enzyme Lp-PLA2in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2in therapy and a method of screening compounds to identify those compounds.
REFERENCES:
patent: 5019508 (1991-05-01), Johnson et al.
patent: 5108899 (1992-04-01), Allen
patent: 5210017 (1993-05-01), Carlsson et al.
patent: 5279957 (1994-01-01), Gross
patent: 5527698 (1996-06-01), Knopf et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5532152 (1996-07-01), Cousens et al.
patent: 5605801 (1997-02-01), Cousens et al.
patent: 5641669 (1997-06-01), Cousens et al.
patent: 5656431 (1997-08-01), Cousens et al.
patent: 5698403 (1997-12-01), Cousens et al.
patent: 5847088 (1998-12-01), Cousens et al.
patent: 5880273 (1999-03-01), Adachi et al.
patent: 5968818 (1999-10-01), Gloger et al.
patent: 5977308 (1999-11-01), Cousens et al.
patent: 5981252 (1999-11-01), MacPhee et al.
patent: 6045794 (2000-04-01), Cousens et al.
patent: 6099836 (2000-08-01), Cousens et al.
patent: 6146625 (2000-11-01), Cousens et al.
patent: 6177257 (2001-01-01), Macphee et al.
patent: 6203790 (2001-03-01), Cousens et al.
patent: 7045329 (2006-05-01), MacPhee et al.
patent: 7052862 (2006-05-01), MacPhee et al.
patent: 7217535 (2007-05-01), MacPhee et al.
patent: 359425 (1989-08-01), None
patent: 509719 (1992-10-01), None
patent: 658205 (2000-03-01), None
patent: 673426 (2001-06-01), None
patent: 04346797 (1992-12-01), None
patent: 07059597 (1995-03-01), None
patent: 10017600 (1998-01-01), None
patent: WO 94/20069 (1994-09-01), None
patent: WO 95/00649 (1995-01-01), None
patent: WO 95/09921 (1995-04-01), None
patent: WO 97/12984 (1997-04-01), None
patent: WO 89/09818 (1998-10-01), None
patent: WO 98/44158 (1998-10-01), None
patent: WO 99/09147 (1999-02-01), None
patent: WO 99/64627 (1999-12-01), None
patent: WO 00/24910 (2000-05-01), None
patent: WO 00/32808 (2000-06-01), None
The Merck Manuals Online Medical Library, [online]. Whitehouse Station, NJ: Merck Research Laboratories, 2006-2007. [retrieved on Jun. 9, 2007]. Retrieved from the Internet: < URL: http://www.merck.com/mmpe/sec07/ch072/ch072b.html#sec07-ch072-ch072b-474 >. Atherosclerosis, pp. 1-8.
Milionis et al. Kidney International, 1999, 56:2276-2285.
Kern et al. J. Lipid Research 1990, 31:17-26.
Masao et al. J Clin Invest 1988, 82:1983-1991.
Vadas et al. Infection and Immunity 1992, 60:3928-3931.
Hurt-Camejo et al Circulation Research. 2001, 89:298-304.
Go et al. Clinica Chimica Acta 1987, 163:63-73.
Chandrakumar N.S., et al, “Stereospecific Synthesis of Ehter Phospholipids Preparation of a-Alkyl-2-(acylamino)-2 deoxyglycerophosphoryl cholines”,J. Org. Chem. 1983 1197-1202.
Christofferson R., et al. “Ribozymes as Human Therapuetic Agents”,J. Of Medicinal Chem. 1994 2023-2037.
Kim U.T., et al., “Synthesis of Phospholipid Head groups via Nucleophilic Ring Opening of 1.3.2.-Dioxaphospholanes”,J. Chem. Commun. 1993 70-71.
Kohler G., et al., “Continuous cultures of fused cells secreting antibody of predefined specificity”,Nature1975 256:495-497.
Langlais J. et al., “Platelet-activating factor acetyl-hydrolase in human semen:a novel decapacitation factor”,Biol. Of Reprod. 1991 44:(Suppl. 1):94.
Ponpipom M.M., et al., “Synthesis of Azide and Amide Analogs of Platelet-Activating Factors and Related Derivatives”,Chem. Phys. Lipids1984 35:29-37.
San H., et al., “Safety and Short Term Toxicity of a Novel and Catonic Formulation for Human Gene Therapy”,Human gene Therapy1993 781-798.
Sevier E.D., et al., “Monoclonal antibodies in clinical immunology”,Clinical Chem. 1981 27:1797-1806.
Stafforini D., et al., Human plasma platelet-activating factor acetylhydrolase,J. Biol. Chem. 1987 262(9):4224-4230.
Yamamoto et al. (1990) Formation of lipid hydroperoxides in the cupric ion-induced oxidation of plasma and low density lipoprotein. Oxid. Damage Repair, Int. Soc. Free Radical Res. Bienn. Meeting. Meeting Date 1990, pp. 287-291. Editor: K. J. A. Da, Jan. 1990.
Stafforini et al., “The Platelet-activating Factor Acetylhydrolase from human erythrocytes”, Journal of Biological Chemsitry 1993 vol. 268; 6; 3856-3865.
Stafforini et al., “Platelet activating factor acetylhydrolase from human plasma”, Methods in Enzymology 1990 187; 344-57. Kohler G, et al., Nature 256:495-497 (1975).
Sevier, ED, et al., Clinical Chem. 27:1797-1806 (1981).
Chandrakumar NS, et al.; :Stereospecific Synthesis of Ehter Phospholipids. Preparation of a-Alkyl-2-(acylamino)-2 deoxyglycerophosphoryl cholines, J. Org. Chem., 1197-1202 (1983).
Ponpipom MM, et al., Synthesis of Azide and Amide Analogs of Platelet-Activating Factors and Related Derivatives, Chem. Phys. Lipids;35:29-37 (1984).
Stafforini D, et al., “Human plasma platelet-activating factor acetylhydrolase,” J. Biol. Chem. 262(9): 4224-4230 (1987).
Stafforini D, et al. “Human macrophages secrete plate-activating factor actylhydrolase,” J. Biol. Chem. 265(17):9682-9687 (1990).
Langlais J. et al., Platelet-activating factor acetyl-hydrolase in human semen:a novel decapacitation factor? Biol. of Reprod. 44 (Suppl. 1):94 (1991).
San H, et al. “Safety and Short Term Toxicity of a Novel and Cationic Formulation for Human Gene Therapy,” Human Gene Therapy: 781-798 (1993).
Kim UT, et al. “Synthesis of Phospholipid Head groups via Nucleophilic Ring Opening of 1.3.2-Dioxaphospholanes,” J. Chem. Commun.: 70-71 (1993).
Christoffersen R, et al. “Ribozymes as Human Theraputic Agents,” J. of Medicinal Chem.: 2023-2037 (1994).
Stull R, et al., “Antigene, Ribozyme, and Aptomer Nucleic Acid Drugs: Progress and Prospects,” Pharm. Res. 1995.
Kohler G, et al., Nature 256:495-497 (1975).
U.S. Appl. No. 08/886,152, filed Jun. 18, 1996.
English Translation of JP 04346797, Aug. 29, 1988.
English Translation of JP 07059597, Oct. 19, 1989.
Hirashima et al., “Platelet-activating factor (PAF) concentration and PAF acetylhydrolase activity in cerebrospinal fluid of patients with subarachnoid hemorrhage”, J. Neurosurg 1994 80:31-36.
Kuby, Janis, “Immunology” 1991 W.H. Freeman 80-83.
Satoh et al., “Platelet-Activating Factor Acetylhydrolase in Plasma Lipoproteins From Patients With Ischemic Stroke”, Stroke 1992 23:1090-1092.
Satoh et al., “Activity of Platelet-Activating Factor (PAF) Acetylhydrolase in Plasma from Patients with Ischemic Cerebrovascular Disease”, Prostaglandins 1988 35(5):685-698.
Stafforini et al., “Platelet-activating Factor Acetylhydrolases”, J. Biol. Chem. 1997 272(29):17895-17898.
Washburn, W.N. and Dennis, E.A. “Novel General Approach for the Assay and Inhibition of Hydrolytic Enzymes Utilizing Suicide-Inhibitory Bifunctional Linked substrates (SIBLINKS):Exemplified in a Phospholipase Assay” J. Am. Chem. Soc. 1990 112:2040-2041.
Washburn, W.N. and Dennis, E.A. “Suicide-inhibitory Bifunctionally Linked Substrates (SIBLINKS) as Phospholipase A2 Inhibitors” J. Biol. Chem. 1991 266(8):5042-5048.
Yoshida et al., “Platelet-activating factor acetylhydrolase activity in red blood cell-stroma from patients with cerebral thrombosis”, Acta Neurol Scand 1992 86:199-203.
Adjei et al., “Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers”, Pharm. Res. 7(6):565-569 (1990).
Basran et al., “Properties of Platelet Activating Factor (PAF-ACETHER) Which Suggest Involvement in Chronic Inflammation and Persistent Asthma”, Br. J. Pharmacol. 77:437 (1982).
Braquet et al., “Effect of Endothelin-1 on Blood Pressure and Bronchopulmonary System of the Guinea Pig”, J. Cardio. Pharm. 13 (Supp.5):S143-S146 (1989).
Brenner, “The Molecular Evolution of Genes and Proteins: A Tale of Two Serines”, Nature 334:528-530 (1988).
Campbell, Biology 3rd Ed., p. 104-106 (1993).
Capecchi,
MacPhee Colin H.
Tew David Graham
Licata & Tyrrell P.C.
McCollum Keith R.
O'Hara Eileen B.
SmithKline Beecham P.L.C.
Wen Sharon
LandOfFree
Lipoprotein associated phospholipase A2, inhibitors thereof... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipoprotein associated phospholipase A2, inhibitors thereof..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoprotein associated phospholipase A2, inhibitors thereof... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015697